Talphera closed at $1.05 on Nov 4, up 0.96%, 28.6% below its 52-week closing high. Volume of 92.5K shares was 1.35× its 20-day average (above normal).
Split-adjusted performance: -5.4% over one month, +20.7% over six months, -25.5% over one year.
Short interest was 1.1M shares at the Oct 15 settlement, up 47.7% from the prior report (4.1% of float, 6.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| TLPHTalphera | $1.05 | +0.96% | +20.7% | — | — | — | $54.5M | |
| OSTXOS Therapies Incorporated | $1.15 | −0.86% | −33.5% | — | — | — | $53.8M | Compare |
| BOLDBoundless Bio | $2.40 | +0.84% | +51.9% | — | — | — | $55.5M | Compare |
| ONCYOncolytics Biotech | $0.4248 | +8.92% | −53.8% | — | — | — | $55.7M | Compare |
| RFLRafael Holdings | $1.07 | −0.93% | −14.4% | −30.3% | −3760.7% | — | $55.8M | Compare |
| HOWLWerewolf Therapeutics | $1.09 | +1.87% | +67.6% | — | 17.5% | — | $53.0M | Compare |
| PLRXPliant Therapeutics | $0.8518 | −1.03% | −30.7% | — | — | — | $52.7M | Compare |
| HRTXHeron Therapeutics | $0.2986 | +4.88% | −77.2% | +1.3% | −14.6% | — | $56.7M | Compare |
| RNTXRein Therapeutics | $0.6587 | −1.32% | −43.7% | — | — | — | $56.8M | Compare |
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
